Protocol No.: CL04-ORY-1001

An escalation/expansion, Open label, Multicenter study of iadademstat and gilteribinib in patients with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) with FMS-like tyrosine kinase mutation (FLT3 mut+): The FRIDA Study
Principal Investigator
Sdrimas, Konstantinos
Phase
I
Age Group
Adult
Applicable Disease Sites
Leukemia
Multiple Myeloma
Participating Institution
Mary Babb Randolph Cancer Center
Contact
Abby Swiger, RN
Research Nurse
Phone: +1 304-293-1683

View on ClinicalTrials.gov